Surveillance of Adverse Events Following Immunization (AEFI) after Third Dose Booster Vaccination with mRNA-Based Vaccine in Universitas Indonesia Hospital Health Personnel
Authors:
- Rakhmad HidayatRHRakhmad Hidayat
- Alyssa Putri MustikaAMAlyssa Putri Mustika
- Fhathia AvishaFAFhathia Avisha
- Zlatikha DjuliannisaaZDZlatikha Djuliannisaa
- Dinisa Diah WinariDWDinisa Diah Winari
- Ria Amiliah PutriRPRia Amiliah Putri
- Heydi Marizky LismanHLHeydi Marizky Lisman
- Vandra DavinVDVandra Davin
- Alvina WidhaniAWAlvina Widhani
- Muhammad Hafiz AiniMAMuhammad Hafiz Aini
- Meilisa RahmadaniMeilisa Rahmadani
- Novita Dwi IstantiNINovita Dwi Istanti
Open Access
Abstract
Facing the rising cases of with higher fatalities COVID-19, some countries decided to give the third dose of vaccine as a booster. As of 9 January 2022, 90.31% of health workers in Indonesia have received the third dose vaccine. This study aims to provide an evaluation of adverse events following immunization (AEFI) in a single center in Indonesia to form a basis for ensuring safety for booster administration nationally. A retrospective, cross-sectional study was conducted using an online survey. Demographic data, AEFI complaints, and factors influencing AEFIs were evaluated. In this study, there were a total of 311 subjects were gathered. The most common AEFI symptoms found at onset <24 h to 28 days were pain at the injection site, fever, shoulder pain, and headache. Most of the AEFI severity of <24 h to 28 days post-vaccination was grade 1 (reduced or uninterrupted daily activities). There was a significant correlation between AEFI and several factors, such as the history of drug allergy, exercise after vaccination, age, BMI < 25, history of symptoms after the first and second vaccinations, and history of COVID-19. There was no anaphylactic reaction in this study. Several AEFI should be considered for the third dose of COVID-19 vaccine administration.Keywords
This publication has 17 references indexed in Scilit:
- Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational studyThe Lancet Infectious Diseases, 2021
- Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 VaccineJAMA Dermatology, 2021
- Reactogenicity Following Receipt of mRNA-Based COVID-19 VaccinesJAMA, 2021
- Non‐life‐threatening adverse effects with COVID‐19 mRNA‐1273 vaccine: A randomized, cross‐sectional study on healthcare workers with detailed self‐reported symptomsJournal of Medical Virology, 2021
- mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested ApproachThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineNew England Journal of Medicine, 2021
- COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines2021
- Catechin synergistically potentiates mast cell-stabilizing property of caffeineAllergy, Asthma & Clinical Immunology, 2021
- An mRNA Vaccine against SARS-CoV-2 — Preliminary ReportNew England Journal of Medicine, 2020
- COVID-19 Vaccines: Current Status and Implication for Use in Indonesia2020